Etoposid Infusion
Etoposide
20mg/ml
EBEWE PHARMA
| Pack size | POM |
|---|---|
| Dispensing mode | |
| Source | 2021-04-01 00:00:0 |
| Agent | |
| Retail Price | AED |
Indications
Etoposid Infusion is used for:
Lung cancer, Testicular cancer
Adult Dose
Intravenous
Testicular Cancer
50-100 mg/m²/day IV on days 1-5, OR
100 mg/m²/day IV on days 1, 3, 5
Repeat q3-4week
Small-Cell Lung Cancer
35 mg/m²/day IV for 4 days, OR
50 mg/m²/day IV for 5 days; repeat q3-4week
Oral
Small cell lung cancer
Adult: Twice the IV dose, rounded to the nearest 50 mg.
Child Dose
Renal Dose
Renal Impairment
CrCl >50 mL/min: Dose adjustment not necessary
CrCl 15-50 mL/min: 75% of regular dose
CrCl < 15 mL/min: Not studied; consider further dose reductions
Administration
Contra Indications
Hypersensitivity, pregnancy, lactation.
Precautions
Skin reactions may occur with accidental exposure; renal or hepatic disease. Periodic CBCs should be done before, during and after therapy. Increased risk of etoposide-toxicity in patients with low serum albumin. Acrylic material has been shown to crack and leak when used with undiluted etoposide inj.
Lactation: not known if excreted in breast milk, discontinue drug or do not nurse
Pregnancy-Lactation
Pregnancy: Based on animal data and its mechanism of action, etoposide can cause fetal harm when administered to a pregnant woman; etoposide, the active moiety of etoposide phosphate is teratogenic in mice and rats advise pregnant women of potential hazard to a fetus; advise women of childbearing potential to avoid becoming pregnant
Advise females of reproductive potential to use effective contraception during treatment and for 6 months after final dose In females of reproductive potential, may cause infertility and result in amenorrhea; premature menopause can occur; recovery of menses and ovulation is related to age at treatment
Lactation: There is no information regarding presence of etoposide in human milk or its effects on breastfed infant milk production; because of potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment with etoposide
Interactions
Synergism with other cytotoxic drugs. Caution when admin with drugs that inhibit phosphatase activity. Cyclosporin A may reduce the clearance of etoposide.
Adverse Effects
Side effects of Etoposide :
>10%
Leukopenia (60-91%), Nausea and Vomiting (30-40%), Thrombocytopenia (28-41%), Alopecia (20-90%), Anorexia (13%), Diarrhea (13%), Leukopenia (60-91%), Anemia (≤33%)
1-10%
Pancytopenia (7%), Stomatitis (6%), Hepatic toxicity (3%), Type 1 hypersensitivity (2%), Orthostatic hypotension (1-2%), Peripheral neuropathy (1-2%)
Frequency Not Defined
Malaise, Shivering, Asthenia, Fever, Mucous membrane inflammation, Hyperuricemia, Local soft tissue toxicity has been reported following extravasation; see section on IV information for extravasation management
Potentially Fatal: Severe myelosuppression, characterised by leucopaenia and thrombocytopaenia. Cardiotoxicity. Anaphylaxis.
Mechanism of Action
Etoposide is a derivative of podophyllotoxin that inhibits DNA synthesis resulting in the arrest of the cell cycle. At low doses, it inhibits cells from entering cell cycle and at high doses, cells entering mitosis are lysed.
Note
Etoposid 20mg/ml Infusion manufactured by EBEWE PHARMA. Its generic name is Etoposide. Etoposid is availble in United Arab Emirates.
Farmaco UAE drug index information on Etoposid Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.